Read on Twitter
#ESCCongress has ended. A unique conference! An unforgettable conference! These are my highlights!
Firstly, an amazing DIGITAL experience... Brining everyone together, breaking all barriers, diminishing borders.
@Barbara_Casadei @Steph_Achenbach @mmamas1973 @DrMarthaGulati
Firstly, an amazing DIGITAL experience... Brining everyone together, breaking all barriers, diminishing borders.
@Barbara_Casadei @Steph_Achenbach @mmamas1973 @DrMarthaGulati
In an earlier (still ongoing) Poll from today... 77% wished to have a hybrid Digital and In Person conference... That would certainly have lots of attractions especially for those who wouldn't other be able to afford it #ESCCongress
https://twitter.com/vass_vassiliou/status/1300702205696192512?s=20
@MarziaRigolli
https://twitter.com/vass_vassiliou/status/1300702205696192512?s=20
@MarziaRigolli
...& now the science! In random order (depending on which I could find in my twitter thread most easily!)
No 1. #Covid and the HEART
HTN, Lipids, Diabetes, CAD, heart failure, ALL associated with worse prognosis (critical events & deaths)
Women have it less severely
#EPeeps
No 1. #Covid and the HEART
HTN, Lipids, Diabetes, CAD, heart failure, ALL associated with worse prognosis (critical events & deaths)
Women have it less severely
#EPeeps
No 2. #Covid & RAAS inihition- The BRACE Corona #ESCCongress
From Brazil! RCT Stop ACEi/ARB or not in covid, showed the safety of ACEi/ARB. In fact there was even possibly a suggestion that continuing is better. But bottom line SAFETY is safeguarded.
@JoaoLCavalcante @pabeda1
From Brazil! RCT Stop ACEi/ARB or not in covid, showed the safety of ACEi/ARB. In fact there was even possibly a suggestion that continuing is better. But bottom line SAFETY is safeguarded.
@JoaoLCavalcante @pabeda1
No 3. EMPEROR-Reduced #ESCCongress
Apart from that the Emperor in this study was far from reduced! Empagliflozin in heart failure showed improved CVS death or hospitalisation. A much needed study brining great news! Monetary cost to be considered though!
#epeeps @ShrillaB
Apart from that the Emperor in this study was far from reduced! Empagliflozin in heart failure showed improved CVS death or hospitalisation. A much needed study brining great news! Monetary cost to be considered though!
#epeeps @ShrillaB
No 4 Explorer-HCM... #ESCCongress
Much needed break-through study for HCM patients. Mavacamten, a new class cardiac myocyte modulator, showing significant improvement in Phase 3 study. This one can say "REMEMBER MY NAME"!
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31792-X/fulltext
#cardioed @Hragy #echofirst
Much needed break-through study for HCM patients. Mavacamten, a new class cardiac myocyte modulator, showing significant improvement in Phase 3 study. This one can say "REMEMBER MY NAME"!
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31792-X/fulltext
#cardioed @Hragy #echofirst
No 5 #ESCCongress
The 2020 ESC AF guidelines...Lots of info here that makes practical sense
Assess the risk & treat accordingly... It is 126 pages, so I cann't summarise in one tweet... but here is my tweetorial on this
https://twitter.com/vass_vassiliou/status/1300202649099304964?s=20
#epeeps @wordfinga @mencardio
The 2020 ESC AF guidelines...Lots of info here that makes practical sense
Assess the risk & treat accordingly... It is 126 pages, so I cann't summarise in one tweet... but here is my tweetorial on this
https://twitter.com/vass_vassiliou/status/1300202649099304964?s=20
#epeeps @wordfinga @mencardio
No 6 #ESCCongress
The 2020 NSTEMI guidelines.
Again lots of information but Diego @drdargaray summarised it all VERY NICELY!
https://twitter.com/drdargaray/status/1299959083106283520?s=20
@mmamas1973 @VijayKunadian @CardioIAN @aayshacader @mirvatalasnag @TharushaGunawa4 @merinopoulos @ohanloncmr @anna_multitask
The 2020 NSTEMI guidelines.
Again lots of information but Diego @drdargaray summarised it all VERY NICELY!
https://twitter.com/drdargaray/status/1299959083106283520?s=20
@mmamas1973 @VijayKunadian @CardioIAN @aayshacader @mirvatalasnag @TharushaGunawa4 @merinopoulos @ohanloncmr @anna_multitask
No 7 #ESCCongress The LODOCO2 study
Apart from a COOL name...This study showed 0.5mg Colchicine- a cheap, repurposed drug improves survival in chronic coronary disease. Reduced outcomes HR 0.69; 95% confidence interval [CI] 0.57–0.83; p<0.001
NO LONGER JUST A GOUT TREATMENT
![No 7 #ESCCongress The LODOCO2 studyApart from a COOL name...This study showed 0.5mg Colchicine- a cheap, repurposed drug improves survival in chronic coronary disease. Reduced outcomes HR 0.69; 95% confidence interval [CI] 0.57–0.83; p<0.001NO LONGER JUST A GOUT TREATMENT](https://pbs.twimg.com/media/Eg3hdJ3X0AE-Zbv.jpg "No 7 #ESCCongress The LODOCO2 studyApart from a COOL name...This study showed 0.5mg Colchicine- a cheap, repurposed drug improves survival in chronic coronary disease. Reduced outcomes HR 0.69; 95% confidence interval [CI] 0.57–0.83; p<0.001NO LONGER JUST A GOUT TREATMENT")
![No 7 #ESCCongress The LODOCO2 studyApart from a COOL name...This study showed 0.5mg Colchicine- a cheap, repurposed drug improves survival in chronic coronary disease. Reduced outcomes HR 0.69; 95% confidence interval [CI] 0.57–0.83; p<0.001NO LONGER JUST A GOUT TREATMENT](https://pbs.twimg.com/media/Eg3hdJ4XYAA-cR_.jpg "No 7 #ESCCongress The LODOCO2 studyApart from a COOL name...This study showed 0.5mg Colchicine- a cheap, repurposed drug improves survival in chronic coronary disease. Reduced outcomes HR 0.69; 95% confidence interval [CI] 0.57–0.83; p<0.001NO LONGER JUST A GOUT TREATMENT")
![No 7 #ESCCongress The LODOCO2 studyApart from a COOL name...This study showed 0.5mg Colchicine- a cheap, repurposed drug improves survival in chronic coronary disease. Reduced outcomes HR 0.69; 95% confidence interval [CI] 0.57–0.83; p<0.001NO LONGER JUST A GOUT TREATMENT](https://pbs.twimg.com/media/Eg3hdJ8XYAAsT5V.jpg "No 7 #ESCCongress The LODOCO2 studyApart from a COOL name...This study showed 0.5mg Colchicine- a cheap, repurposed drug improves survival in chronic coronary disease. Reduced outcomes HR 0.69; 95% confidence interval [CI] 0.57–0.83; p<0.001NO LONGER JUST A GOUT TREATMENT")
![No 7 #ESCCongress The LODOCO2 studyApart from a COOL name...This study showed 0.5mg Colchicine- a cheap, repurposed drug improves survival in chronic coronary disease. Reduced outcomes HR 0.69; 95% confidence interval [CI] 0.57–0.83; p<0.001NO LONGER JUST A GOUT TREATMENT](https://pbs.twimg.com/media/Eg3hdJ6WsAIJCFb.jpg "No 7 #ESCCongress The LODOCO2 studyApart from a COOL name...This study showed 0.5mg Colchicine- a cheap, repurposed drug improves survival in chronic coronary disease. Reduced outcomes HR 0.69; 95% confidence interval [CI] 0.57–0.83; p<0.001NO LONGER JUST A GOUT TREATMENT")
Apart from a COOL name...This study showed 0.5mg Colchicine- a cheap, repurposed drug improves survival in chronic coronary disease. Reduced outcomes HR 0.69; 95% confidence interval [CI] 0.57–0.83; p<0.001
NO LONGER JUST A GOUT TREATMENT
No 8 #ESCCongress
Women had less cardiac disease than men
but unfortunately received LESS secondary prevention therapy 
THIS NEEDS TO CHANGE... EDUCATION, EDUCATION & MORE EDUCATION
@DrMarthaGulati @purviparwani @ErinMichos @iamritu @biljana_parapid @ShrillaB @hvanspall
Women had less cardiac disease than men
but unfortunately received LESS secondary prevention therapy THIS NEEDS TO CHANGE... EDUCATION, EDUCATION & MORE EDUCATION@DrMarthaGulati @purviparwani @ErinMichos @iamritu @biljana_parapid @ShrillaB @hvanspall
No 9- the penultimate one! #ESCCongress
This is not everyone's cup of tea- but it is an amazing piece! AI analysed HFpEF ECG in SR could "predict" future AF. This is amazing as #preventive measures can be instigated and timely anticoagulation. I think the future is bright!
This is not everyone's cup of tea- but it is an amazing piece! AI analysed HFpEF ECG in SR could "predict" future AF. This is amazing as #preventive measures can be instigated and timely anticoagulation. I think the future is bright!
And the last one! No 10 #ESCCongress
Looking my tweets, I felt this one deserves a TOP 10! Let's Kill the p value!! by Prof Pocock.. his argument: it is not just a p value, it is the type of study, the clinical impact, a 0.06 in correct setting might be > powerful than a 0.04
Looking my tweets, I felt this one deserves a TOP 10! Let's Kill the p value!! by Prof Pocock.. his argument: it is not just a p value, it is the type of study, the clinical impact, a 0.06 in correct setting might be > powerful than a 0.04
... And by popular demand (and requests!) we have a no 11 and 12! So No 11 #ESCCongress A VERY IMPORTANT GUIDELINE ON PHYSICAL ACTIVITY AND SPORTS.... we must all move! Target... 150 mins per week! @exerciseworks @MichaelPapadak2 @SSharmacardio @s_gati @MarcDweck @mmamas1973
& the final No 12! #ESCCongress A community led study by non-physician-HCW improved #adherence, lowered BP & lowered CVS risk! In 
& 
Together we can get BP lower & IMPROVE OUTCOMES @AnastasiaSMihai @ecgrhythms @ISHBP @ALEX_MISCHIE @iamritu #epeeps @VijayKunadian @EkateriniL
& Together we can get BP lower & IMPROVE OUTCOMES @AnastasiaSMihai @ecgrhythms @ISHBP @ALEX_MISCHIE @iamritu #epeeps @VijayKunadian @EkateriniL
